- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04508803
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer: a muLti-centEr Phase II Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Performance Status 0-1.
- Life expectancy longer than 3 months.
- Histological proven unresectable recurrent or advanced breast cancer.
- For ehe main research: Patients with histopathologically diagnosed advanced (recurrent or metastatic) HER2-negative breast cancer with definite pathogenic/suspected pathogenic germline mutations in BRCA1/2, or PALB2, or CHEK2.
- For ancillary exploration research 1: Patients with histopathologically diagnosed advanced (recurrent or metastatic) HER2-negative breast cancer with definite pathogenic/suspected pathogenic germline mutations in ATM, or ATR, or BAP1, or BARD1, or BLM, or BRIP1, or CHEK1, or CDK12, or FANCA, or FANCC, or FANCD2, or FANCE, or FANCF, or FANCM, or MRE11A, or NBN, or PTEN, or RAD50, or RAD51C, or RAD51D, or WRN.
- For ancillary exploration research 2: Patients with histopathologically diagnosed advanced (recurrent or metastatic) HER2-positive breast cancer with definite pathogenic/suspected pathogenic germline mutations in BRCA1/2, or PALB2, or CHEK2, or ATM, or ATR, or BAP1, or BARD1, or BLM, or BRIP1, or CHEK1, or CDK12, or FANCA, or FANCC, or FANCD2, or FANCE, or FANCF, or FANCM, or MRE11A, or NBN, or PTEN, or RAD50, or RAD51C, or RAD51D, or WRN.
- For ancillary exploration research 3: Patients with histopathologically diagnosed advanced (recurrent or metastatic) breast cancer with brain and with metastases definite pathogenic/suspected pathogenic germline mutations in BRCA1/2, or PALB2, or CHEK2, or ATM, or ATR, or BAP1, or BARD1, or BLM, or BRIP1, or CHEK1, or CDK12, or FANCA, or FANCC, or FANCD2, or FANCE, or FANCF, or FANCM, or MRE11A, or NBN, or PTEN, or RAD50, or RAD51C, or RAD51D, or WRN.
- Not more than 2 - line chemotherapy regimens were received in the stage of recurrence and metastasis.Platinum-based or PARP1 inhibitor treatment may be accepted, but the patient must have no disease progression during or within 8 weeks of the end of platinum-based or PARP1 inhibitor treatment at the stage of recurrence and metastasis, and relapse within 12 months after the end of neoadjuvant/adjuvant therapy.
- Patients with hormone-receptor-positive, HER2 negative must received at least first-line endocrine therapy and progress to the stage of recurrence or metastasis, or have disease recurrence or metastasis during adjuvant endocrine therapy or within 1 year after the end of adjuvant therapy.
- At least one extracranial measurable disease according to the response evaluation criteria in solid tumor (RECIST 1.1).
- All patients enrolled are required to have adequate hematologic, hepatic, and renal function
- Women of childbearing age must have a pregnancy test (serum or urine) that is negative within 7 days of enrollment, and be willing to use an appropriate method of contraception during the study and 8 weeks after the last dose of the study drug.
- Be able to understand the study procedures and sign informed consent.
Exclusion Criteria:
- Pregnant or lactating women.
- Treatment with an investigational product within 4 weeks before the first treatment.
- Subjects have any active autoimmune disease, history of autoimmune disease, or history of disease or syndrome requiring systemic steroid or immunosuppressive medication.
- Subjects had a history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disorders.
- Received chemotherapy, radiotherapy, targeted therapy and major surgery within 3 weeks before the first administration;Received endocrine therapy within 2 weeks prior to first administration.
- Uncontrolled serious infection.
- Patients with hypertension and uncontrolled hypertension with hypotensive drugs therapy (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg). Patients with grade I or above myocardial ischemia or myocardial infarction or arrhythmia (including QT interval ≥ 440 ms) or cardiac insufficiency.
- Inability to swallow, gastrointestinal resection, chronic diarrhea and obstruction of the intestine, various factors which affect drug use and absorption.
- Patients with active viral hepatitis B or C.
- Patients with chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.
- Have received prior treatment with anti-PD-1/PD-L1 drugs and PARP inhibitors;
Patient who has a history of psychotropic substance abuse and is unable to stop or have a history of mental disorders.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The main research
Patients diagnosed with HER2 negative metastatic breast cancer with BRCA1/2, PALB2, CHEK2 pathogenic/suspected pathogenic germline mutation are recruited.
|
Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
|
Experimental: Ancillary Exploration research 1
Patients diagnosed with HER2 negative metastatic breast cancer with DDR gene (include ATM、ATR、BAP1、BARD1、BLM、BRIP1、CHEK1、CDK12、FANCA、FANCC、FANCD2、FANCE、FANCF、FANCM、MRE11A、NBN、PTEN、RAD50、RAD51C、RAD51D、WRN)pathogenic/suspected pathogenic germline mutation except BRCA1/2, PALB2 and CHEK2 are recruited.
|
Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
|
Experimental: Ancillary Exploration research 2
Patients diagnosed with HER2 positive metastatic breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation are recruited.
|
Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
|
Experimental: Ancillary Exploration research 3
Patients diagnosed with brain metastases breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation who has not undergone or progressed after brain radiotherapyare recruited.
|
HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle. Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to approximately 12 weeks
|
ORR is the percentage of participants with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.
CR = Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
|
Up to approximately 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Up to approximately 30 months
|
Time from date of randomization to the date of death from any cause
|
Up to approximately 30 months
|
Progression-Free Survival (PFS)
Time Frame: Up to approximately 30 months
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause.
Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant.
If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
|
Up to approximately 30 months
|
Clinical Benefit Rate (CBR)
Time Frame: Up to approximately 12 weeks
|
Percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1.CR = Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease: PD = At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm.
|
Up to approximately 12 weeks
|
Duration of Response (DOR)
Time Frame: Up to approximately 10 months
|
Time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer
|
Up to approximately 10 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHANGEABLE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment Efficacy
-
Johns Hopkins UniversityCompleted
-
Medigene AGTerminatedFeasibility | Tolerability | Safety | Treatment EfficacyGermany
-
University Hospital HeidelbergCompletedSelf Efficacy | Treatment Outcome | Inpatient Psychotherapy | Group Cohesion
-
ARJ Medical, Inc.RecruitingHelicobacter Pylori Infection | Efficacy | Post-TreatmentUnited States
-
Cairo UniversityNot yet recruitingEfficacy of Treatment of Cellulite Using Carboxy Therapy
-
MinaPharm PharmaceuticalsUnknownr-Hirudin (Thrombexx) Efficacy in Treatment of HaematomasEgypt
-
Alexandria UniversityCompletedDrug Side Effect | Treatment Efficacy | Clinical EfficacyEgypt
-
Second Affiliated Hospital, School of Medicine,...First Affiliated Hospital of Jinan University; First Affiliated Hospital of... and other collaboratorsRecruitingEvaluate the Efficacy of Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic WoundsChina
-
University of ZurichUnknownTreatment Efficacy | Monotherapy | Dolutegravir | Primary HIV InfectionSwitzerland
-
Queen Mary Hospital, Hong KongNot yet recruitingQuality of Life | Burns | Self Efficacy | Burn Injury | Adherence, Treatment | Burn Second Degree | Burns Third DegreeChina
Clinical Trials on HX008,Niraparib
-
Taizhou Hanzhong biomedical co. LTDNot yet recruiting
-
Taizhou Hanzhong biomedical co. LTDRecruiting
-
Taizhou Hanzhong biomedical co. LTDUnknown
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid TumorsChina
-
Taizhou Hanzhong biomedical co. LTDUnknown
-
Shanghai Miracogen Inc.RecruitingAdvanced Malignant Solid TumorsChina
-
Taizhou HoudeAoke Biomedical Co., Ltd.Unknown
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
Tesaro, Inc.Completed
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States